Daniel Adu-Ampratwum, PhD
Research Assistant Professor
Many organic small molecules serve as drug leads for drug discovery and drug development programs. Understanding the structure and mechanism of action of these small molecules is essential for drug lead optimization. Also having a reliable synthetic access to these organic small molecules is important to aid in SAR studies and lead optimization in the search for new drugs for various diseases. Dr. Adu-Ampratwum's area of interest includes exploring novel synthetic methods for the synthesis of small organic molecules as lead compounds for drug discovery. His current research area focuses on designing and synthesizing small molecules to study HIV and cancer biology and as potential therapeutics.
Other research areas:
Division of Medicinal Chemistry & Pharmacognosy,
Cancer
Jonathan Boyce, PhD
Assistant Professor
Dr. Boyce's lab develops protease-cleavable linkers for peptide prodrugs and antibody-drug conjugates (ADCs) to minimize neutropenia, a common side effect for FDA-approved protease-cleavable ADCs due to premature drug release. The Boyce lab designs biomolecular prodrugs to combat cancer resistance in ccRCC, ovarian, and breast cancers, and focuses on the chemical synthesis, medicinal chemistry optimization, and target evaluation of natural product classes with rare selectivity against cancer.
His lab's research interests focus on protease-activated prodrug development, prodrug linker optimization for cancer therapeutics, biomolecular prodrug development to combat cancer resistance, chemical synthesis of natural product analogs with rare selectivity against cancer, and synthesis of photoaffinity probes for target ID.
His lab's research interests focus on protease-activated prodrug development, prodrug linker optimization for cancer therapeutics, biomolecular prodrug development to combat cancer resistance, chemical synthesis of natural product analogs with rare selectivity against cancer, and synthesis of photoaffinity probes for target ID.
James Fuchs
Associate Dean for Research and Graduate Studies
The research in Dr. Fuchs' lab focuses on the design and preparation of bioactive molecules for therapeutic applications against cancer and infectious diseases. His lab utilizes fundamental chemical knowledge and synthetic methodology to facilitate the process of drug discovery and development through the generation of biological probe molecules, the synthesis and modification of lead compounds, and the optimization of drug properties. The overarching goals of these studies are to understand the mechanisms through which small molecules interact with proteins or other biomolecules in the context of disease progression and to improve the potential utility of promising new compounds to help them advance toward the clinic. Recently, the Fuchs lab has collaborated with numerous labs in the areas of natural product drug development for various cancers, the preparation of protein degraders active against leukemia, and HIV-1 capsid and integrase drug development.
Other research areas:
Cancer,
Infectious Diseases,
Natural Products,
Division of Medicinal Chemistry & Pharmacognosy
Pui Kai (Tom) Li, PhD
Associate Professor
Dr. Li’s research interest focuses on the design, syntheses and studies of small molecules for cancers and infectious diseases. In the cancer area, our group focus on prostate and pancreatic cancer. Novel molecules are developed using the strategies of drug repurposing and structure-based drug design (in collaboration with Dr. Xiaolin Cheng). In the research of infectious disease, our focus is on the development of small molecules for the treatment of COVID-19. Novel molecules are generated through computational chemistry, molecular modeling and virtual screening targeting the interface of spike protein and human ACE-2 receptor.
Blake R. Peterson, PhD
Chair of the Division of Medicinal Chemistry & Pharmacognosy
Dr. Peterson’s research group works to design, synthesize, and discover small molecules that affect the proliferation of cancer cells and associated immune cells that support malignancy. To identify these compounds, the Peterson laboratory synthesizes fluorescent molecular probes as tools for drug discovery. These probes are used to create target-based or phenotypic drug discovery assays to identify anticancer agents with novel mechanisms of action. To optimize and evaluate these compounds, they use synthetic organic chemistry, medicinal chemistry, and chemical biology approaches. In conjunction with high throughput screening by confocal microscopy, flow cytometry, and other related techniques, his laboratory identifies chemical probes of biological systems, uncovers mechanisms of biologically active agents, and discovers hit and lead compounds for the development of therapeutics.